Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.85) EPS for the quarter, Zacks reports.
Titan Pharmaceuticals Stock Performance
Shares of TTNP stock opened at $4.19 on Friday. Titan Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $14.80. The business has a 50-day moving average of $3.62 and a 200 day moving average of $4.08.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Titan Pharmaceuticals in a research report on Monday, March 17th. They set a “sell” rating on the stock.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- How to Invest in Insurance Companies: A Guide
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
- What Do S&P 500 Stocks Tell Investors About the Market?
- MarketBeat Week in Review – 03/17 – 03/21
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
